CLDN7

CLDN7 is a four-transmembrane tight junction protein that maintains epithelial barrier integrity and participates in cell-cell adhesion signaling. Its C-terminal YV motif directly binds the PDZ1 domains of ZO-1, ZO-2, and ZO-3, anchoring it to the cytoplasmic tight junction scaffold (PMID:10601346). Beyond canonical TJ function, CLDN7 directly interacts with EpCAM in glycolipid-enriched membrane microdomains and serves as an obligate scaffold for assembly of the EpCAM/CO-029/CD44v6 complex in tetraspanin-enriched microdomains, conferring apoptosis resistance in colorectal cancer cells (PMID:16054130, PMID:17579117). In vivo, intestinal loss of CLDN7 disrupts paracellular barrier integrity, activates Wnt/β-catenin signaling to promote colitis-associated tumorigenesis, and dysregulates gut microbiota composition, while its transcription is positively regulated by ACSS2-mediated H4K12 crotonylation, a pathway suppressed by TNF-α through m6A-dependent ACSS2 mRNA destabilization (PMID:34026335, PMID:39004000, PMID:40650658).

1. 1999 High

   Establishing CLDN7 as a tight junction structural component resolved its basic subcellular role within the newly defined claudin family, and identification of direct PDZ1-mediated binding of ZO-1/2/3 to the claudin C-terminal YV motif revealed the molecular link between claudins and the cytoplasmic TJ plaque.

   Evidence HA-tagged CLDN7 transfection and immunolocalization in MDCK cells; in vitro PDZ domain pulldown assays and co-recruitment in L fibroblasts

   PMID:10601346 PMID:9892664

   Open questions at the time

   • Stoichiometry of ZO–CLDN7 complexes not determined
   • Contribution of CLDN7 to paracellular ion selectivity not isolated from other claudins
   • Post-translational regulation of the YV–PDZ interaction unknown
2. 2005 High

   Discovery that CLDN7 directly associates with EpCAM in lipid rafts, with phosphorylation restricted to this raft-localized pool, expanded CLDN7 function beyond canonical TJ sealing to adhesion-signaling scaffolding in specialized membrane domains.

   Evidence Co-immunoprecipitation with membrane-permeable cross-linker, sucrose density gradient lipid raft fractionation, immunofluorescence co-localization

   PMID:16054130

   Open questions at the time

   • Kinase responsible for raft-restricted CLDN7 phosphorylation unidentified
   • Phosphorylation site(s) on CLDN7 not mapped
   • Whether EpCAM binding requires CLDN7 phosphorylation not tested
3. 2007 High

   Demonstrating that CLDN7 is the obligate scaffold for EpCAM/CO-029/CD44v6 complex assembly in tetraspanin-enriched microdomains, and that this complex confers apoptosis resistance, established a non-TJ oncogenic function for CLDN7.

   Evidence Reciprocal co-IP with CLDN7 siRNA knockdown in colorectal cancer cells, sucrose gradient TEM fractionation, apoptosis assays

   PMID:17579117

   Open questions at the time

   • Direct binding interfaces between CLDN7 and CO-029/CD44v6 not mapped
   • Whether scaffold function operates in non-cancerous epithelia unknown
   • Downstream apoptosis resistance mechanism not fully delineated
4. 2010 High

   Identification of ECL1 residues 32 and 48 as determinants of CLDN7's inability to associate with CD81 (and consequent lack of HCV receptor activity) provided the first residue-level functional map of CLDN7's extracellular loop specificity.

   Evidence FRET-based stoichiometric imaging, site-directed mutagenesis of CLDN7 ECL1, HCV pseudoparticle entry assay

   PMID:20375010

   Open questions at the time

   • Full structural basis of ECL1 selectivity unresolved—no crystal or cryo-EM structure of CLDN7
   • Whether residues 32/48 influence paracellular selectivity not tested
   • Trans-interaction partners of CLDN7 ECL2 not identified
5. 2021 High

   Intestinal conditional knockout of Cldn7 proved it is required in vivo for TJ integrity and intestinal homeostasis, and revealed that its loss activates Wnt/β-catenin signaling to promote colitis-associated tumorigenesis, linking barrier failure to a specific oncogenic pathway.

   Evidence Inducible villin-CreERT2 Cldn7 conditional KO mice, AOM/DSS model, FITC-dextran permeability, immunofluorescence, Western blot for β-catenin

   PMID:34026335

   Open questions at the time

   • Direct mechanism by which CLDN7 loss activates Wnt/β-catenin not established
   • Whether CLDN7 physically interacts with Wnt pathway components not tested
   • Relative contribution of barrier leak versus CLDN7 signaling to tumorigenesis not separated
6. 2024 Medium

   The finding that CLDN7-deficient intestinal inflammation is partly mediated by dysregulated gut microbiota—transferable by co-housing and reversible by antibiotics—added a host-microbiome axis to CLDN7's barrier-protective function.

   Evidence Cldn7 conditional KO mice, 16S rRNA sequencing, antibiotic depletion, co-housing transfer of inflammatory phenotype

   PMID:39004000

   Open questions at the time

   • Specific microbial species or metabolites driving inflammation not identified
   • Whether microbiota changes are secondary to barrier leak or CLDN7-specific signaling unclear
   • Single-lab finding awaiting independent replication
7. 2025 High

   Identification of the TNF-α → m6A-ACSS2 → H4K12 crotonylation → CLDN7 transcriptional axis provided the first chromatin-level regulatory mechanism for CLDN7 expression and a pharmacologically targetable node (crotonate) for barrier restoration in colitis.

   Evidence ChIP-seq for H4K12cr at the CLDN7 locus, ACSS2 genetic/pharmacologic inhibition, m6A sequencing of ACSS2 mRNA, TEER and permeability assays, crotonate rescue in mice and intestinal epithelial cells

   PMID:40650658

   Open questions at the time

   • Whether other histone acylation marks cooperate with H4K12cr at the CLDN7 promoter not explored
   • Identity of the m6A reader destabilizing ACSS2 mRNA not determined
   • Relevance to extra-intestinal epithelia not tested

• No high-resolution structure of CLDN7 exists, the direct mechanism linking CLDN7 loss to Wnt/β-catenin activation is unknown, and the functional significance of raft-restricted CLDN7 phosphorylation remains undefined.
• No cryo-EM or crystal structure of CLDN7
• Phosphorylation sites and responsible kinases uncharacterized
• Whether CLDN7 directly modulates Wnt pathway components or acts indirectly via barrier disruption is unresolved